Wegovy 7.2mg in Singapore: What the STEP UP Trial Reveals About Breaking Through Weight Loss Plateaus
Hitting a weight loss plateau is one of the most frustrating experiences for anyone on a medical weight management journey. You’ve been consistent with your treatment, following your doctor’s guidance, and seeing steady progress — then the scale stops moving. If you’re currently on Wegovy 2.4mg and your weight has remained stagnant for weeks or months, you’re not alone. And importantly, a new option is on the horizon.
Clinical research is now pointing toward a higher dose — Wegovy 7.2mg — that may help patients break through plateaus and achieve further weight reduction. This article examines the science behind weight loss plateaus, the landmark STEP UP trial results, and how Singapore patients may access this treatment through the Health Sciences Authority (HSA) Named Patient Programme.
Why Weight Loss Plateaus Happen — Even on Effective Treatment
A weight loss plateau is not a sign that treatment has failed. It is a well-documented physiological response that occurs as the body adapts to a lower body weight. Understanding why plateaus happen helps patients make informed decisions about their next steps.
Metabolic adaptation is the primary driver. As you lose weight, your body requires fewer calories to maintain its new, smaller size. Your resting metabolic rate drops — sometimes by more than what would be expected from weight loss alone. This is the body’s evolutionary defence against starvation, and it affects nearly everyone who loses a significant amount of weight.
Hormonal counter-regulation also plays a role. Weight loss triggers increases in ghrelin (the hunger hormone) and decreases in leptin (the satiety hormone), creating a biological environment that resists further weight reduction. Even GLP-1 receptor agonists like semaglutide — the active ingredient in Wegovy — must work against these powerful homeostatic forces.
For patients on Wegovy 2.4mg who have reached a plateau, the question becomes: can a higher dose overcome these adaptive mechanisms? The STEP UP clinical trial was designed to answer exactly that.
What Is Wegovy 7.2mg?
Wegovy 7.2mg is an investigational higher dose of semaglutide — three times the currently approved maintenance dose of 2.4mg. It contains the same active ingredient (semaglutide, a GLP-1 receptor agonist) but at a higher concentration, designed for patients who may benefit from additional metabolic support beyond what the standard dose provides.
It is important to understand that Wegovy 7.2mg is not yet commercially available in Singapore through retail pharmacies. It is currently accessible only through the HSA Named Patient Programme, which allows registered medical clinics to import unregistered therapeutic products for specific patients under medical supervision.
The STEP UP Trial: Key Findings
The STEP UP trial was a phase 3 clinical study conducted between January 1, 2023, and November 26, 2024, evaluating the efficacy and safety of semaglutide 7.2mg compared to semaglutide 2.4mg and placebo in adults with obesity or overweight with weight-related comorbidities.
The results were significant. Among participants who were fully adherent to the treatment protocol and accompanying lifestyle modifications, Wegovy 7.2mg demonstrated:
- Average weight loss of up to 20.7% of baseline body weight
- An additional 3% weight reduction for patients whose weight had plateaued on Wegovy 2.4mg
- Clinically meaningful improvements in cardiometabolic risk factors
The additional 3% may sound modest, but in clinical terms it is meaningful. For a patient weighing 100kg, a 3% additional loss represents 3kg of further weight reduction — beyond what was already achieved on the 2.4mg dose. Over time, this additional loss can translate into meaningful health benefits, particularly for obesity-related conditions.
| Metric | Wegovy 2.4mg | Wegovy 7.2mg |
|---|---|---|
| Average weight loss (fully adherent) | ~17.5% | Up to 20.7% |
| Additional loss for plateau patients | — | ~3% beyond 2.4mg results |
| Study period | January 2023 – November 2024 | |
| Trial phase | Phase 3 (STEP UP) | |
Who May Benefit from Wegovy 7.2mg?
Wegovy 7.2mg is being studied primarily for patients who meet the following profile:
- Currently on Wegovy 2.4mg and tolerating the treatment well
- Weight has plateaued for a sustained period (typically 8–12 weeks or more) despite adherence to treatment and lifestyle recommendations
- No significant tolerability issues at the 2.4mg dose that would contraindicate dose escalation
- Under the ongoing care of a qualified medical practitioner who can assess suitability and monitor progress
This is not a starting dose. Patients who are new to GLP-1 treatment would begin at lower doses and titrate upward under medical supervision, following established protocols. The 7.2mg dose is specifically being studied for those who have already demonstrated tolerance to semaglutide at the standard maintenance dose.
Access Through the HSA Named Patient Programme
In Singapore, therapeutic products that are not yet registered with the Health Sciences Authority can be imported for specific patients through the Named Patient Programme (NPP). This is a regulated pathway that allows doctors to bring in unregistered medicines when they determine there is a clinical need that cannot be met by registered alternatives.
Under the NPP, the importing clinic handles the entire process on behalf of the patient:
- The doctor assesses the patient and determines medical suitability
- The clinic submits an application to HSA for approval to import
- Upon HSA approval, the product is ordered and shipped from the manufacturer
- The medication is delivered to the clinic, where the patient receives it under medical supervision
Patients do not need to handle any paperwork or deal with HSA directly. The entire process is managed by the medical clinic.
What to Expect: The Import Timeline
Because Wegovy 7.2mg is not yet commercially stocked in Singapore, patients should be aware of the expected timeline from initial enquiry to receiving treatment:
| Stage | What Happens | Estimated Duration |
|---|---|---|
| 1. Medical Consultation | Doctor assesses suitability, reviews medical history, confirms plateau status | Same day |
| 2. HSA Application | Clinic submits Named Patient Programme application to HSA | 2–4 weeks |
| 3. Product Shipment | Upon HSA approval, medication is ordered and shipped from manufacturer | 2–3 weeks |
| 4. Clinic Delivery | Medication arrives at clinic; patient is notified for collection and administration | 1 week |
| Total estimated timeline | ~8 weeks | |
This timeline is an estimate. Actual durations depend on HSA processing times, manufacturer stock availability, and shipping logistics. The clinic will keep patients informed at each stage of the process.
Safety and Side Effect Profile
The STEP UP trial also evaluated the safety profile of the 7.2mg dose. As with any dose escalation of a GLP-1 receptor agonist, gastrointestinal side effects — including nausea, vomiting, diarrhoea, and constipation — were the most commonly reported. These were generally mild to moderate in severity and tended to diminish over time.
This is why medical supervision is essential. The decision to escalate to a higher dose must be made by a doctor who knows the patient’s full medical history, current tolerance, and treatment goals. No patient should attempt to adjust their dosage independently.
Frequently Asked Questions
Is Wegovy 7.2mg approved by HSA?
Wegovy 7.2mg is not yet registered as a commercial product with the HSA. It is accessible through the Named Patient Programme, which permits importation of unregistered therapeutic products for individual patients under medical supervision when clinically indicated.
How much additional weight loss can I expect on 7.2mg?
The STEP UP trial showed an average additional weight loss of approximately 3% for patients whose weight had plateaued on the 2.4mg dose. Individual results vary based on adherence to treatment, lifestyle factors, metabolic response, and other variables.
Can I switch directly from Wegovy 2.4mg to 7.2mg?
Dose escalation protocols are determined by the prescribing doctor based on individual patient assessment. The transition is medically supervised and follows a titration schedule appropriate to the patient’s tolerance and clinical needs.
What if I’m not currently on Wegovy 2.4mg?
Wegovy 7.2mg is being studied for patients already on the 2.4mg maintenance dose. If you are new to medical weight management or currently on a different treatment, your doctor will discuss the most appropriate starting point for your situation. The standard Wegovy titration begins at 0.25mg and increases gradually.
Is the 7.2mg dose safe?
The STEP UP trial data indicate a safety profile consistent with the known effects of GLP-1 receptor agonists. The most common side effects are gastrointestinal and typically mild to moderate. As with any prescription treatment, the prescribing doctor evaluates individual risk factors before recommending dose escalation.
How do I find out if I’m eligible?
The first step is a medical consultation. Your doctor will review your weight loss history on the current dose, assess your tolerance, and determine whether Wegovy 7.2mg through the Named Patient Programme is appropriate for your situation.
Will I need to pay for the HSA application?
The Named Patient Programme process is handled by the clinic. Costs associated with the importation process, consultation, and treatment will be discussed during your medical consultation so you have full transparency before proceeding.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Wegovy (semaglutide) is a prescription-only medicine that must be prescribed by a registered medical practitioner. Always consult a qualified healthcare professional for medical concerns, diagnosis, or treatment. Individual results vary. The STEP UP trial data referenced in this article is from published clinical research.
Interested in Learning More?
NuLifeCare is one of the few clinics in Singapore directly importing Wegovy 7.2mg under the HSA Named Patient Programme. If you are currently on Wegovy 2.4mg and your weight has plateaued, we invite you to speak with our medical team about whether the higher dose may be appropriate for you.
Contact us at 6844 1528 or visit our booking page to schedule a consultation. The overall process — including HSA approval, product shipment, and delivery — may take up to eight weeks.
NuLifeCare
📍 Blk 325 Ubi Avenue 1 #01-701, Singapore 400325
📞 6844 1528
📧 contact@nulifecare.com.sg